Source - Alliance News

Solvonis Therapeutics PLC on Monday said the US Patent & Trademark Office has allowed a core patent application covering compounds in its artificial-intelligence-enabled central-nervous-system discovery programme, granting protection in the US’s drug market for at least 18 years.

The application, titled ‘bridged ring compounds and their therapeutic use as CNS agents’, received a first-action allowance with no objections or rejections, Solvonis said. Allowance means the patent will be issued once administrative formalities are complete, expected in the coming months.

The London-based biotechnology company, which focuses on developing therapeutics for mental health and substance use disorders, said the patent secures rights to both the composition and therapeutic use of a group of morpholine-class compounds.

These molecules were originally developed by Awakn Life Sciences Corp and now form a core part of Solvonis’s proprietary central nervous system compound library.

Chief Scientific Officer David Nutt said the decision ‘strengthens the foundation of our discovery platform and provides long-term protection for a chemically distinct series of CNS-active compounds already integrated into our AI-supported programme’.

Chief Executive Anthony Tennyson added that the favourable outcome ‘validates the early-stage innovation acquired through Awakn and enhances the strategic value of our AI-enabled platform’.

Shares in Solvonis were up 2.2% at 0.18 pence in London on Monday morning.

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Solvonis Therapeutics PLC (SVNS)

-0.04p (-13.56%)
delayed 15:57PM
JavaScript chart by amCharts 3.4.4